A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to...

Full description

Bibliographic Details
Main Authors: Zakaria Alameddine, Muhammad Rafay Khan Niazi, Anisha Rajavel, Jai Behgal, Praneeth Reddy Keesari, Ghada Araji, Ahmad Mustafa, Chapman Wei, Abdullah Jahangir, Terenig O Terjanian
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Current Oncology
Subjects:
castrate-resistant prostate cancer
PARP inhibitors
progression-free survival
overall survival
homologous recombination repair genes
Online Access:https://www.mdpi.com/1718-7729/30/10/669

Internet

https://www.mdpi.com/1718-7729/30/10/669

Similar Items